Lv3
318 积分 2022-09-16 加入
Choosing a drug to treat motion sickness
14小时前
待确认
BTKi-induced cardiovascular toxicity in CLL: Risk mitigation and management strategies
1天前
已完结
Laser tattoo removal strategies: Part II: A review of the methods, techniques, and complications involved in tattoo removal
2天前
已完结
PIRTOBRUTINIB IN COVALENT BTK-INHIBITOR PRE-TREATED MANTLE CELL LYMPHOMA: UPDATED RESULTS AND SUBGROUP ANALYSIS FROM THE PHASE 1/2 BRUIN STUDY WITH 2 YEARS OF SURVIVAL FOLLOW-UP
3天前
已完结
JSH practical guidelines for hematological malignancies, 2023: leukemia-5. Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
3天前
已完结
JSH practical guidelines for hematological malignancies, 2023: II. Lymphoma 4. Mantle cell lymphoma (MCL)
3天前
已完结
Pirtobrutinib, a Non-Covalent (reversible) BTK Inhibitor, in Mantle Cell Lymphoma Patients Previously Treated with a Covalent BTK Inhibitor: Results from a China Phase 2 Study
3天前
已完结
Mantle Cell Lymphoma: Optimal Treatment With Bruton Tyrosine Kinase–Targeted Approaches
3天前
已完结
Pirtobrutinib in relapsed or refractory mantle cell lymphoma: a profile of its use
3天前
求助中
Efficacy and Safety of a Water-Free Topical Cyclosporine, 0.1%, Solution for the Treatment of Moderate to Severe Dry Eye Disease
14天前
已完结
皖公网安备34019202002308
